Key Takeaways
- Hope Biosciences’ phase 2 trial shows its stem cell therapy may enhance motor function in Parkinson’s patients.
- The treatment group experienced a significant reduction in motor function scores compared to the placebo group.
- The company is planning to advance to a phase 3 trial pending FDA discussions.
Study Overview
Hope Biosciences has announced promising results from its phase 2 trial of an allogeneic adipose-derived mesenchymal stem cell therapy for patients with early to moderate Parkinson’s disease. The trial involved 60 participants who were randomly assigned to receive either six infusions of the stem cell therapy or a placebo over 32 weeks. The rationale behind using stem cells for Parkinson’s treatment lies in their ability to provide neuroprotection, stimulate neuroregeneration, and differentiate into neural progenitor cells while migrating to areas affected by neurodegeneration.
The primary efficacy endpoint for the trial, as listed on ClinicalTrials.gov, was MDS-UPDRS Part II, a patient-reported motor function scale. The study also focused on MDS-UPDRS Part III, which is clinician-rated, and other safety measures. By the end of the treatment regimen, patients who received the stem cell therapy showed a mean reduction of 9.82 points on the clinician-rated Part III scale, compared to a mere 0.5 points in the placebo group. A reduction of 3.25 points is considered the minimal clinically important difference, indicating that the treatment group had significant improvement in motor function.
Donna Chang, president of the Hope Biosciences Research Foundation and the study’s sponsor, expressed optimism regarding the findings, emphasizing that repeated treatments may be crucial for sustained motor function enhancement in Parkinson’s patients. While the trial’s press release primarily highlighted the clinician-rated results, it did not include data from Part II. Chang acknowledged that there were “divergent results” between the clinician-rated assessments and patient-reported outcomes but framed these discrepancies as validation of the study design rather than a question of the treatment’s effectiveness.
Chang noted, “The subjective nature of patient reporting is something that must be balanced in trial design through inclusion of more objective data-gathering mechanisms that are vital for evaluating therapeutic benefit.” She emphasized that when considering all the data from the trial, a clear treatment effect emerges.
Hope Biosciences is currently preparing for discussions with the FDA to finalize the results of the phase 2 trial and is hopeful about progressing to a phase 3 confirmatory trial for its stem cell therapy candidate. The upcoming meetings aim to discuss the next steps in advancing this therapy toward potential regulatory approval, which could pave the way for new treatment options for individuals living with Parkinson’s disease.
The content above is a summary. For more details, see the source article.